Capstone Investment Advisors, LLC Gilead Sciences, Inc. Call Options Transaction History

Capstone Investment Advisors, LLC

$30.4 Billion
Q3 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $392,881 - $495,540	5,900 Added 11.52%	57,100 $4.79 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $1.13 Million - $1.3 Million	17,900 Added 53.75%	51,200 $3.51 Million
Q1 2024 May 01, 2024	SELL	$71.58 - $87.29 $1.48 Million - $1.81 Million	-20,700 Reduced 38.33%	33,300 $2.44 Million
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $1.86 Million - $2.11 Million	25,400 Added 88.81%	54,000 $4.37 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $761,582 - $830,901	-10,300 Reduced 26.48%	28,600 $2.14 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $182,424 - $208,080	2,400 Added 6.58%	38,900 $3 Million
Q1 2023 May 09, 2023	BUY	$77.31 - $88.08 $2.57 Million - $2.92 Million	33,200 Added 1006.06%	36,500 $3.03 Million
Q4 2022 Feb 10, 2023	SELL	$62.32 - $89.47 $903,640 - $1.3 Million	-14,500 Reduced 81.46%	3,300 $283,000
Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $89,310 - $102,015	-1,500 Reduced 7.77%	17,800 $1.1 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $3.75 Million - $4.22 Million	-64,900 Reduced 77.08%	19,300 $1.19 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $8.43 Million - $10.6 Million	-145,600 Reduced 63.36%	84,200 $5.01 Million
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $8.42 Million - $9.56 Million	-129,800 Reduced 36.1%	229,800 $16.7 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $751,359 - $810,633	11,100 Added 3.19%	359,600 $25.1 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $787,028 - $859,939	-12,400 Reduced 3.44%	348,500 $24 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $5.09 Million - $5.81 Million	84,900 Added 30.76%	360,900 $23.3 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $3.63 Million - $4.13 Million	64,000 Added 30.19%	276,000 $16.1 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $6.68 Million - $8.4 Million	107,600 Added 103.07%	212,000 $13.4 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $7.36 Million - $8.54 Million	101,700 Added 3766.67%	104,400 $8.03 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $14.5 Million - $18.5 Million	-230,900 Reduced 98.84%	2,700 $202,000
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $3.29 Million - $3.62 Million	53,400 Added 29.63%	233,600 $15.2 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $2.09 Million - $2.3 Million	33,400 Added 22.75%	180,200 $11.4 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $3.46 Million - $3.89 Million	56,000 Added 61.67%	146,800 $9.92 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $2.35 Million - $2.63 Million	37,600 Added 70.68%	90,800 $5.9 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $865,722 - $1.13 Million	-14,300 Reduced 21.19%	53,200 $3.33 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $4.55 Million - $5.04 Million	63,800 Added 1724.32%	67,500 $5.21 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $175,176 - $204,336	2,700 Added 270.0%	3,700 $262,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $72,110 - $85,470	1,000	1,000 $81,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.5 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.99 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.65 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.5 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.

Account